Recently, the field of metabolic bone disease has received prominent recognition because of the increased public awareness of the prevalence and problems associated with osteoporosis. Because of the enormous disability and health care costs resulting from this disease, attempts have been made to try to identify subjects at risk or those who have established disease for either preventive or therapeutic interventions.
Whatever orientation the rheumatologist has chosen as a career-pure immunology, inflammatory diseases in general, or aches and pains syndromes of the musculoskeletal system-there will be confrontation with osteoporosis, either because of the side effects of treatment (corticosteroids), or because of secondary effects of the disease on bone (rheumatoid arthritis (RA)), or because of primary bone rarefaction (vertebral crush fracture). Osteoporosis is defined clinically as loss of bone (osteopenia) to an extent sufficient to result in fracture with minimal trauma, generally of the spine, but also of the hip and wrist. Long before the fractures are manifest radiologically the patient has unknowingly already progressively lost 30-50% of his or her bone capital over the previous [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] years. Although osteoporosis is the most common of the diseases that affect bone, the condition, as a well defined disease entity, remains problematic. Analogous syndromes include congestive heart failure, renal insufficiency, hepatic failure, mental deficiency, arterial insufficiency, and respiratory insufficiency. All these syndromes have a commmon physiopathology-namely, insufficient organ reserves to meet intercurrent minor stress.
Because of the confusion in the use of the term osteoporosis the National Institute of Health (USA) Consensus Conference on Osteoporosis in 1984 formulated the following definition for osteoporosis. Primary osteoporosis is an age related disorder characterised by decreased bone mass and by increased susceptibility to fracture in the absence of other recognisable causes of bone loss. Secondary osteoporosis is then the condition in which osteoporosis and fractures are the result of excessive bone resorption in specific endocrinopathies and arthropathies, or of excessive and prolonged use of drugs which interfere with bone metabolism, as for example corticosteroids.
Identification of those who are at risk If osteoporosis is to be prevented the first step is to identify those at risk in good time. The bone depleting effect of oestrogen deficiency is well reported. Patients at high risk for primary and secondary osteoporosis are women with premature oestrogen deficiency, whether of surgical or natural origin, who clearly require oestrogen substitution treatment. Knowledge of factors other than oestrogen deficiency that are likely to cause or aggravate bone loss related to age and sex is of clinical value for prediction and counselling purposes.
CLINICAL CRITERIA There seems to be general agreement that small, thin, fair, pale skinned women (especially those of northern European extraction), spinsters or mothers of only one or two children, those with strong family histories of hip and spine fracture, and those who, in addition to the foregoing criteria, are heavy smokers run an appreciably higher fracture risk (table) .
It is of clinical interest to note that osteoporosis and generalised osteoarthrosis are rarely seen together, though both are common in the older age group. Current data suggest that there are real differences between the two conditions.3
As the first clinical signs of generalised osteoarthrosis (Heberden and Bouchard nodes) are readily seen in the hand joints in the perimenopausal period, these can be useful in eliminating a group of women who are probably not at risk of developing symptomatic osteoporosis and thus do not need preventive treatment. There have been a number of controversial reports about the systemic effect of RA on bone metabolism. Parathyroid overactivity and hypercalcaemia, as well as osteomalacia, have been described as part of the rheumatoid process. Rheumatoid arthritis affects more women (premenopausal and postmenopausal) than men and leads to chronic immobility in some but not in others. It is accompanied by serum protein alterations and requires a variety of drug treatment regimens. All these factors have an influence on bone remodelling indices, so that evaluation of the effect of RA is complicated and very difficult. 2 For these reasons we studied prospectively bone metabolism indices in a homogeneous group of postmenopausal women who were in hospital owing to an exacerbation of their disease.
Patients with RA who had never had steroid treatment differed from the control population as they had significantly higher serum phosphorus concentrations, alkaline phosphatase activity, and osteocalcin concentrations. Calcitropic hormone concentrations (parathyroid hormone, 25-hydroxyand 1 ,25-dihydroxyvitamin D concentrations) were normal. Serum calcium concentrations were also normal when corrected for serum albumin. Excretion of urinary hydroxyproline and glycosaminoglycan was significantly increased.'1'5 These biochemical data indicate that in postmenopausal patients with RA there is an increase in metabolic bone activity. This observation is in agreement with whole body technetium (99"Tc) retention studies, which showed a generalised increase in bone turnover in patients with RA not treated with steroids. '6 Using single and dual photon absorptiometry in postmenopausal patients with RA, we found a significantly reduced peripheral bone mineral content at the radius, but a normal bone mineral content in the lumbar spine. 7 Similarly, using dual quantitative computed tomography, we found no decrease in pure trabecular bone density in postmenopausal women (Dequeker and Van Holsbeek, unpublished data). In a recent study, however, low trabecular bone density was found in a small number of young patients with RA.'8 In young patients with RA the same group also found low trabecular bone volume at the iliac crest. '9 Although in RA the data suggest a higher metabolic bone activity, no increased bone loss in the vertebral column was detected, possibly owing to inhibition of prostaglandin E2 synthesis by non-steroidal anti-inflammatory drugs. Massive osteolysis in RA occurs rarely and is usually associated with other concomitant diseases.20
Corticosteroids and the skeleton in rheumatoid arthritis The question of whether or not, or to what extent, corticosteroids produce or enhance the osteoporosis of RA has been much debated.2' There is no doubt that high doses of corticosteroids, >7 5 mg prednisone daily, are deleterious for the skeleton at all ages in a number of cases but more so in children and after the menopause. [22] [23] [24] Low dose corticosteroid treatment in our hands did not seem to alter the bone mineral content in the peripheral or in the axial skeleton. " The latter finding is surprising as in the group treated with corticosteroids a significantly (p<001) higher incidence of fractures of the vertebrae or femoral neck occurred.
Other authors, using subjective density grading of x rays of the spine, have also been unable to show significant differences between patients with RA treated or not treated with corticosteroids despite the occurrence of more vertebral fractures in the treated group. 25 The explanation for these contradictory observations-no corticosteroid induced changes in bone mineral content in the spine but a high incidence of fractures in the group treated with corticosteroids-is not clear, but possibly, corticosteroids alter the quality of the bone rather than the quantity of bone mineral.
The mechanism by which corticosteroids may alter bone quality is unknown. Low doses of prednisone (5 mg fig 2.33 The mechanism of bone turnover is complicated, entailing communication between several cell types, which respond to systemic hormones and locally released factors. The sequence of successive activation of bone cells is started by recruitment of bone resorbing osteoclasts to the remodelling site. The resorption phase is followed by the arrival of osteoblasts, which replace the bone excavated by the osteoclasts. Mononuclear cells of the monocyte/macrophage lineage may be involved in the coordination of the two phases. The rates of bone resorption and formation are closely related, and this tight 'coupling' is conserved under many pathological conditions. Coupling of the catabolic and anabolic phases of bone remodelling may also explain the ability of the major bone resorbing hormones, parathyroid hormone and 1,25-dihydroxyvitamin D3, to stimulate bone formation. Clearly, the concept of bone cell coupling is important for the interpretation of inflammatory tissue reactions in bone.
In addition to direct cell contact, interactions of the osteoblast and osteoclast lineages may entail the release of messenger molecules. Bone surface lining cells may generate signals governing the recruitment of osteoclasts. This hypothesis is strengthened by the observation that osteoblasts, but not osteoclasts, express receptors for the bone resorbing hormones, parathyroid hormone and 1,25-dihydroxyvitamin D3. Moreover, matrix constituents are potent chemoattractants for bone resorbing cells, and osteoblasts may 'uncover' the resorption site by hormone regulated release of matrix degrading enzymes. Similarly, the recruitment and proliferation of osteoblasts following resorption may depend on autocrine or paracrine growth factors positioned in the bone matrix, or released locally by osteoblasts or mononuclear cells34 (fig 3) . Figure 3 gives the proposed function of 1,25-dihydroxyvitamin D3, lymphokines, and cytokine receptors in bone remodelling and immunomodulation. Prostaglandins, monokines, interleukin 1, tumour necrosing factor with interferon gamma and lymphokines may be major regulators of bone destruction and repair in RA. Several systemic and local growth factors probably take part in the chronic inflammatory process, and stimulate bone destruction in addition to reparative processes. 35 1 ,25-Dihydroxyvitamin D3 and retinoid acid affect monolymphokine regulation. Both factors are bone resorbing agents and they also regulate aspects of bone formation. Moreover, these agents enhance the release of interleukin 1 and regulate lymphokine release (interleukins 2 and 3), which may explain some of their actions on bone.
New markers of bone mineral metabolism There is at present an intensive search for markers of bone mineral metabolism which will either help to explain the sequence of bone loss and bone remodelling or identify those persons at risk for osteoporosis. Useful information has been obtained by examination of the roles of collagenous and non-collagenous bone proteins in bone mineral metabolism. 36 Urinary hydroxyproline is used as a marker of bone absorption because hydroxyproline once released from bone is not recycled for collagen biosynthesis. In addition, the proportion of hydroxyproline excreted in the bone seems to be constant so that the rate of excretion is a useful index of the rate of collagen degradation and bone turnover. Hydroxyproline excretion in RA is, however, also correlated with disease activity and not necessarily with bone loss. 13
In osteoporosis urinary hydroxyproline is increased in 'fast bone losers'-that is, those patients in whom resorption is exaggerated, particularly at the menopause. It has recently been claimed that urinary hydroxyproline values, together with body fat index, alkaline phosphatase, and urinary calcium measurements, predict 79% of postmenopausal women with accelerated bone loss. 37 Two hours' fasting morning calcium/creatinine ratio and hydroxyproline/creatinine ratio are the best markers at present for bone resorption because they are not influenced by diet.
SERUM BONE y-CARBOXYGLUTAMIC ACID PROTEIN-OSTEOCALCIN
Bone y-carboxyglutamic acid protein, also called osteocalcin, is the most abundant non-collagenous protein of bone matrix. Circulating bone y-carboxyglutamic acid protein may be measured by specific radioimmunoassay. Bovine osteocalcin cross reacts with human osteocalcin. Several studies have shown that measurement of serum bone ycarboxyglutamic acid protein provides a sensitive and useful marker of bone metabolism in a variety of metabolic bone diseases. At first it was thought that serum osteocalcin concentrations would reflect the amount of bone laid down because the protein is produced by osteoblasts. Because of the coupling between bone resorption (osteoclasts) and bone formation, however, raised osteocalcin concentrations are also found in conditions with a negative bone balance and a high turnover, as in osteoporosis and RA.
Serum osteocalcin shows diurnal variation-concentrations fall during the morning, rise in the afternoon and early evening, and reach a peak at night.38 Seasonal variation with the highest values during winter and the lowest during summer have been noted. Glucocorticosteroid treatment reduces serum osteocalcin concentrations and corticosteroid pulse therapy reduces these concentrations for a long time. 39 Finally, local regulators of skeletal growth, which include polypeptide growth factors, bone and cartilage inducing factors, blood cell derived growth factors, and prostaglandins, may well assume greater importance in the pathogenesis of metabolic bone disease in the future. The actions of these factors, which have been studied mainly in vitro, have been recently reviewed. 35 It seems that at present serum bone y-carboxyglutamic acid protein is the one bone protein that promises to assist in the diagnosis and management of high turnover metabolic bone disease states. If further studies confirm its usefulness in osteoporosis as a predictor of rapid bone loss without the need for bone biopsy this serum marker will then not only allow early detection but also an appropriate choice of treatment in osteoporosis-that is, the use of specific inhibitors of high turnover states, such as oestrogen, calcitonin, or biphosphonates. In low turnover osteoporosis it may also be useful in determining whether the osteoblast may be stimulated to enhance bone formation with treatments such as fluoride, anabolic steroids, parathyroid 
